Genentech’s ACTpen Receives FDA’s Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis

 Genentech’s ACTpen Receives FDA’s Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis

Genentech’s ACTpen Receives FDA’s Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis

Shots:

  • The approval is based on P-I & P-IV study assessing Actemra 162 mg SC via the pre-filled syringe (PFS) vs Actemra 162 mg SC via the ACTPen & testing safety and efficacy of ACTpen respectively
  • The study demonstrated showing a single dose of Actemra 162 mg SC with ACTpen is bioequivalent to currently used PFS device, with no new safety signals observed.
  • ACTpen (162 mg/0.9 mL) is a pre-filled auto-injector, for Actemra an interleukin-6 (IL-6) receptor antagonist, indicated to treat moderate-to-severe RA. It is expected to available for patients in Jan, 2019

Click here to read full press release/ article | Ref: Genentech | Image: HuffPost

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post